Silo Pharma, Inc. announced that its Alzheimer?s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +5.36% | +1.14% | +22.92% |
04-23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
04-10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.92% | 4.78M | |
-1.63% | 89.08B | |
+2.76% | 40.9B | |
-12.92% | 32.25B | |
+54.69% | 25.14B | |
-16.51% | 15.39B | |
-8.27% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- SILO Stock
- News Silo Pharma, Inc.
- Silo Pharma Announces Positive Results in Alzheimer?s Disease Study